*Biocon, *a research-driven, global healthcare company on a *consolidated basis *has registered a drop of 90.33% in the net profit during the quarter ended December 2008.
During the quarter, the profit of the company stood at Rs 282 million for the quarter ended Dec. 31, 2008 as compared to Rs 2,918.20 million for the quarter ended Dec. 31, 2007. Total Income increased 75.18% from Rs 2,582.50 million for the quarter ended Dec. 31, 2007 to Rs 4,524.10 million for the quarter ended Dec.31, 2008. The company reported a substantial drop in *standalone net profit* for the quarter ended December 2008. During the quarter, the profit of the company declined 91.52% to Rs 240.80 million from Rs 2,840.40 million in the same quarter last year. Net sales for the quarter rose 16.11% to Rs 2,254.70 million, while total income for the quarter rose 9.99% to Rs 2,415.50 million, when compared with the prior year period. The company reported earnings of Rs 1.25 a share during the quarter, registering 95.75% decline over prior year period. *Quarterly Results - Standalone (Rs in mn)* *As at* *Dec - 08* *Dec - 07* *%Change* *Net Sales* 2,254.70 1,941.90 16.11 *Net Profit* 240.80 2,840.40 (91.52) *Basic EPS* 1.25 29.39 (95.75) Biocon announced that its subsidiary, Syngene International, Indian biotechnology major, had tied-up with Sapient, a US based biotechnology company to offer fully integrated drug discovery services. --~--~---------~--~----~------------~-------~--~----~ You received this message because you are subscribed to the Google Groups "Kences1" group. To post to this group, send email to [email protected] To unsubscribe from this group, send email to [email protected] For more options, visit this group at http://groups.google.com/group/kences1?hl=en -~----------~----~----~----~------~----~------~--~---
